Mode
Text Size
Log in / Sign up
Phase 4 Completed N=57 Randomized Double-blind Treatment

Loop Diuretics Administration and Acute Heart Failure

Source: ClinicalTrials.gov NCT01441245 ↗
Enrolled (actual)
57
Serious AEs
40.4%
Results posted
Feb 2016
Primary outcomePrimary: Evaluation of Mean Urine Output Volume During the Infusion Period — 2505; 2140 mL — p=0.04

Summary

Intravenous loop diuretics is the therapy most commonly used to treat pulmonary congestion and systemic fluid overload. In theory, continuous infusion should allow for a more consistent diuresis, avoiding the sodium reabsorption in the distal tubule as well as the neurohormonal activation. This should lead to renal function improvement and BNP decrease.

Outcome Measures

OutcomeResultp-value
PRIMARY
Evaluation of Mean Urine Output Volume During the Infusion Period
2505; 2140 0.04 sig
PRIMARY
Evaluation of Renal Function in Terms of Creatinine Levels at Discharge
1.78; 1.51 0.01 sig
PRIMARY
Evaluation of Renal Function in Terms of Changes in Creatinine Levels
-0.10; -0.50 0.02 sig
PRIMARY
Evaluation of B-type Natriuretic Peptide (BNP) Levels From Admission to the End of Treatment
679; 949 0.04 sig
PRIMARY
Change in Brain Natriuretic Peptide (BNP) Levels From Admission to the Discharge
-525; -148 0.03 sig
PRIMARY
Evaluation of Renal Function in Terms of Changes in GFR
-3.18; -1.93 0.01 sig
PRIMARY
Evaluation of Renal Function in Terms of GFR Values at Discharge
44.8; 46.7 0.05
SECONDARY
Length of Hospitalization in the Two Groups
80; 44 <0.01 sig
SECONDARY
Dopamine Infusion During Hospitalization
50; 26 <0.01 sig

Eligibility Criteria

Inclusion Criteria

  • Patients took part in the random sample selection if they met the diagnostic criteria for acute decompensated HF.
  • Patients with primary diagnosis of ADHF, volume overload with cardia dilation and LVEF 100 pg/ml.

Exclusion Criteria

  • Patients were excluded if they had received more than 2 IV doses of furosemide or any continuous infusion of furosemide 1 month before randomization
  • If they had end-stage renal disease or the need for renal replacement therapy, isolated diastolic dysfunction.
  • Recent myocardial infarction
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01441245). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search